Harvard Bioscience Announces Jeffrey A. Duchemin as New CEO

Harvard Bioscience Announces Jeffrey A. Duchemin as New CEO

HOLLISTON, Mass., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.
(Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range
of tools to advance life science research and regenerative medicine, today
announced that its Board of Directors has hired Jeffrey A. Duchemin, a veteran
life science executive, as Harvard Bioscience's Chief Executive Officer. David
Green, who has served as Harvard Bioscience's interim Chief Executive Officer
since May 15, 2013, has resigned from that interim position and will continue
in his capacity as the President of Harvard Bioscience until the completion of
the Company's spin-off of its regenerative medicine subsidiary.

Earl Lewis, Chairman of Harvard Bioscience's Board of Directors, commented,
"Mr. Duchemin is a proven global executive with extensive experience in the
fields of life science research, diagnostic and medical devices. The Board of
Directors is excited to have Jeff join Harvard Bioscience and is looking
forward to working with him to bring further success to the Company."

David Green, the Company's President, added, "As a co-founder of Harvard
Bioscience, and having been its President for over 17 years, I am very pleased
to introduce Jeff as the Company's new CEO.I am one of the Company's largest
shareholders and I have great confidence that Jeff can lead Harvard Bioscience
to the next level of growth and value creation for all our shareholders."

Jeffrey Duchemin stated, "I'm thrilled to join the Harvard Bioscience team and
look forward to leading the company to increased shareholder value through
acquisitions, greater growth in expanding foreign markets, enhanced sales and
marketing efforts and continued internal product development."

Prior to joining Harvard Bioscience, Mr. Duchemin spent 16 years with Becton
Dickinson ("BD") in progressive sales, marketing and executive leadership
positions across BD's three business segments; BD Medical Systems, BD
Diagnostic Systems, and BD Biosciences.In October 2012 BD Biosciences,
Discovery Labware was acquired by Corning Life Sciences.Mr. Duchemin was a
Global Business Director for Corning Life Sciences until his recent departure
to Harvard Bioscience. He is a transformational leader with demonstrated
business results. The depth of his experience spans across a broad range of
life science research and medical device products resulting in growth on a
global basis. Mr. Duchemin earned an M.B.A. from Southern New Hampshire
University and a B.S. in Accounting from the University of Massachusetts

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer
of a broad range of specialized products, primarily apparatus and scientific
instruments, used to advance life science research and regenerative medicine.
Our products are sold to thousands of researchers in over 100 countries
primarily through our 850 page catalog (and various other specialty catalogs),
our website, through distributors, including GE Healthcare, Thermo Fisher
Scientific and VWR, and via our field sales organization. HBIO has sales and
manufacturing operations in the United States, the United Kingdom, Germany,
Sweden and Spain with additional facilities in France and Canada. For more
information, please visit our website at www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are
made pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements include
statements relating to, among other things, the appointment of Mr. Jeffrey
Duchemin as Harvard Bioscience's new Chief Executive Officer. These statements
involve risks and uncertainties, including among other things, market
conditions that may cause results to differ materially from the statements set
forth in this press release. The forward-looking statements in this press
release speak only as of the date of this press release. Harvard Bioscience
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to such statements to reflect any change in its
expectations with regard thereto or any changes in the events, conditions or
circumstances on which any such statement is based.

For investor inquiries, please call (508) 893-8066. Press releases may be
found on our web site.

CONTACT: Jeff Duchemin, CEO
         David Green, President
         Tom McNaughton, CFO
         Tel: 508 893 8999
         Fax: 508 892 6135

Harvard Bioscience, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.